相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
Adriana Marton et al.
NATURE REVIEWS NEPHROLOGY (2021)
Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice
Yihai Liu et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Non-alcoholic fatty liver disease in mice with hepatocyte-specific deletion of mitochondrial fission factor
Yukina Takeichi et al.
DIABETOLOGIA (2021)
Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway
Jingyi Luo et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells
Jing Xu et al.
CELLS (2021)
Combined effect of canagliflozin and exercise training on high-fat diet-fed mice
Kenichi Tanaka et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2020)
Editorial: New Insights into Estrogen/Estrogen Receptor Effects in the Cardiac and Skeletal Muscle
Dawn A. Lowe et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Dynamic Metabolome Analysis Reveals the Metabolic Fate of Medium-Chain Fatty Acids in AML12 Cells
Tatsuya Fushimi et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
Takashi Sasaki et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Inter-Laboratory Comparison of Metabolite Measurements for Metabolomics Data Integration
Yoshihiro Izumi et al.
METABOLITES (2019)
Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis
Yu Hirata et al.
JCI INSIGHT (2019)
Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes
Seigo Sugiyama et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2018)
Widely-targeted quantitative lipidomics method by supercritical fluid chromatography triple quadrupole mass spectrometry
Hiroaki Takeda et al.
JOURNAL OF LIPID RESEARCH (2018)
Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
Kumiko Shiba et al.
SCIENTIFIC REPORTS (2018)
Brown Adipose Tissue Controls Skeletal Muscle Function via the Secretion of Myostatin
Xingxing Kong et al.
CELL METABOLISM (2018)
Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
Laween Uthman et al.
FRONTIERS IN PHYSIOLOGY (2018)
Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice
Farhana Naznin et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
Skeletal muscle inflammation and insulin resistance in obesity
Huaizhu Wu et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Wide target analysis of acylglycerols in miso (Japanese fermented soybean paste) by supercritical fluid chromatography coupled with triple quadrupole mass spectrometry and the analysis of the correlation between taste and both acylglycerols and free fatty acids
Takahiro Ogawa et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2017)
Insulin Regulation of Proteostasis and Clinical Implications
Haleigh A. James et al.
CELL METABOLISM (2017)
Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives
Hongyu Qiu et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2017)
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor
Yumei Ye et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study
Ryotaro Bouchi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
Simon A. Hawley et al.
DIABETES (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
F. Zaccardi et al.
DIABETES OBESITY & METABOLISM (2016)
Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice
Atsushi Obata et al.
ENDOCRINOLOGY (2016)
Insulin and IGF-1 receptors regulate FoxO-mediated signaling in muscle proteostasis
Brian T. O'Neill et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Increased grip strength with sodium-glucose cotransporter 2
Motoaki Sano et al.
JOURNAL OF DIABETES (2016)
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
Chikara Komiya et al.
PLOS ONE (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Human Muscle Fiber Type-Specific Insulin Signaling: Impact of Obesity and Type 2 Diabetes
Peter H. Albers et al.
DIABETES (2015)
FoxO transcription factors: their roles in the maintenance of skeletal muscle homeostasis
Anthony M. J. Sanchez et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2014)
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
J. Bolinder et al.
DIABETES OBESITY & METABOLISM (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
The Relationship between Muscle Fiber Type-Specific PGC-1α Content and Mitochondrial Content Varies between Rodent Models and Humans
Gilles Gouspillou et al.
PLOS ONE (2014)
Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases
Rita Rastogi Kalyani et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Analysis of the Effect of Canagliflozin on Renal Glucose Reabsorption and Progression of Hyperglycemia in Zucker Diabetic Fatty Rats
Chiaki Kuriyama et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Mechanisms for fiber-type specificity of skeletal muscle atrophy
Yichen Wang et al.
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE (2013)
Muscle type and fiber type specificity in muscle wasting
Stefano Ciciliot et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2013)
Slow-Twitch Fiber Proportion in Skeletal Muscle Correlates With Insulin Responsiveness
Charles A. Stuart et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Sarcopenia and Diabetes: Two Sides of the Same Coin
Francesco Landi et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2013)
Mechanisms Modulating Skeletal Muscle Phenotype
Bert Blaauw et al.
COMPREHENSIVE PHYSIOLOGY (2013)
Mitochondrial functional specialization in glycolytic and oxidative muscle fibers: tailoring the organelle for optimal function
Martin Picard et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2012)
A Novel Method to Measure Glucose Uptake and Myosin Heavy Chain Isoform Expression of Single Fibers From Rat Skeletal Muscle
James G. MacKrell et al.
DIABETES (2012)
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Jan Bolinder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Regulation of Physiological and Metabolic Function of Muscle by Female Sex Steroids
Espen E. Spangenburg et al.
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE (2012)
Muscle Fiber Type-Dependent Differences in the Regulation of Protein Synthesis
Craig A. Goodman et al.
PLOS ONE (2012)
Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique
Craig A. Goodman et al.
FASEB JOURNAL (2011)
FIBER TYPES IN MAMMALIAN SKELETAL MUSCLES
Stefano Schiaffino et al.
PHYSIOLOGICAL REVIEWS (2011)
Prevalence and Determinant Factors of Sarcopenia in Patients With Type 2 Diabetes The Korean Sarcopenic Obesity Study (KSOS)
Tae Nyun Kim et al.
DIABETES CARE (2010)
FoxO3 controls autophagy in skeletal muscle in vivo
Cristina Mammucari et al.
CELL METABOLISM (2007)
FoxO3 coordinately activates protein degradation by the Autophagic/Lysosomal and proteasomal pathways in atrophying muscle cells
Jinghui Zhao et al.
CELL METABOLISM (2007)
The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome
Kitt Falk Petersen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Recent advances in the regulation of the TOR pathway by insulin and nutrients
J Avruch et al.
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE (2005)
Dysregulation of the TSC-mTOR pathway in human disease
K Inoki et al.
NATURE GENETICS (2005)
Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy
M Sandri et al.
CELL (2004)
TSC2 mediates cellular energy response to control cell growth and survival
K Inoki et al.
CELL (2003)
Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2
A Garami et al.
MOLECULAR CELL (2003)
AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling.
DR Bolster et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load
TH Reynolds et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
分享论文
